Sequenom同加利福尼亚大学合作开发基于新一代测序的ctDNA检测技术

  美国西格诺（Sequenom）公司今日宣布，他们将同加利福尼亚大学开展合作进行临床研究，用于开发基于新一代测序技术的循环肿瘤DNA（ctDNA）检测技术。
  基于此项合作，加利福尼亚大学Moores癌症研究中心将会测试检测血液中ctDNA实验的可用性，以此来对癌症患者进行监测，并且帮助患者进行疗法的选择。
  西格诺公司首先发表声明表示，他们计划在明年1月同加利福尼亚大学合作开发一种液体活检技术，但具体信息目前尚未透露。
  研究者设计的ctDNA检测试验起初仅仅是用于实体瘤的检测，并且可以覆盖美国FDA批准疗法中的100个癌症相关的基因，这些基因包括专业协会指导方针中的一些基因、和当前临床试验靶向疗法相关的一些基因，或者一些证据确凿的癌症通路相关的一些基因。研究者自出，该项测试最初的焦点是针对晚期的癌症患者，因为这些患者组织样本的活检往往并不可用或风险太高。
  西格诺公司表示，加利福尼亚大学将会是在进行ctDNA检测的一系列全球癌症中心中第一个同他们进行合作的，目前公司计划在2016年将该项测试技术在病人护理中进行推广。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Sequenom, UCSD Collaborate on Liquid Biopsy Assay Study
Sequenom said today that it is collaborating with the University of California, San Diego in a clinical research study of its next-generation sequencing-based circulating tumor DNA assay.

Under the collaboration, UCSD's Moores Cancer Center will test the utility of the assay to profile ctDNA in blood to monitor cancer patients and assist in therapy selection.

Sequenom first announced it intended to develop a liquid biopsy assay in January and at the time said it had partnered with UCSD, but did not provide details of the assay.

The ctDNA assay will initially be designed for research use only in solid tumors and will cover over 100 cancer-related genes that are associated with a US Food and Drug Administration-approved treatment, included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways. The initial focus of the test will be on late-stage cancers where tissue biopsies are not available or are too risky to obtain.

"The ability to match patients to a growing list of treatments and to monitor their response by a simple blood draw promises to make a significant difference in the way we treat cancer patients at UC San Diego," Razelle Kurzrock, director of the Center for Personalized Cancer Therapy & Clinical Trials Office at UCSD, said in a statement.

Sequenom said that the collaboration with UCSD would be the first in a series of collaborations with cancer centers worldwide that will use the ctDNA assay as part of their clinical research programs. The firm plans to bring the assay to market for use in patient care in 2016.